Switching to tenofovir alafenamide in patients with virologically suppressed chronic hepatitis B and renal or hepatic impairment: final week 96 results from an open-label, multicentre, phase 2 study
| Autor: | Janssen, Harry L A a, b, †, *, Lim, Young-Suk c, †, Lampertico, Pietro d, e, Heo, Jeong f, Chen, Chi-Yi g, Fournier, Claire h, Tsang, Tak Yin Owen i, Bae, Ho j, Chen, Chien-Hung k, Coffin, Carla S l, Ahn, Sang Hoon m, Trinh, Huy n, Flaherty, John F o, Abramov, Frida o, Zhao, Yang o, Liu, Yang o, Lau, Audrey o, German, Polina o, p, Chuang, Wan-Long q, Agarwal, Kosh r, Gane, Edward s |
|---|---|
| Zdroj: | In The Lancet Gastroenterology & Hepatology August 2024 9(8):718-733 |
| Databáze: | ScienceDirect |
| Externí odkaz: |
|